Preparing for the Growth of Cold Chain

Approval comes amid positive results of a single-arm trial, showing a complete response rate of 77% in patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.

Allen Jacques explains the history behind medications’ lack of supply, while offering ways to help alleviate their impact.

Technology designed to effectively address blood clots by combining capabilities of larger devices with smaller catheters.

Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.

The latest news for pharma industry insiders.

Approval was based on positive data from Takeda’s Phase III VISIBLE 2 study, which displayed long-term clinical remission in approximately half of patients with Crohn disease receiving Entyvio.